Logo

Lexicon Licenses Gene Target Technology to Immunex

Feb 06, 2001

NEW YORK, Feb 6 – Lexicon said Tuesday it has licensed its gene targeting technology to Immunex, bringing to 14 the number of its sublicensees.

Under the terms of the deal, Lexicon will receive annual license fees, technology usage frees for any model Immunex develops using the technology, as well as milestone payments for future discoveries.

Exact figures were not disclosed.

Lexicon of The Woodlands, Tex., determines gene function using large-scale knockout mouse technology.

It has collaborations and alliances with companies such as Abgenix, Bristol-Myers Squibb, American Home Producs, and DuPont.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.